Trial Profile
Clinical Trial to Compare the Efficacy and Safety of Fixed-doses of VIENA II in Participants With Hypertension and Dyslipidemia
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Rosuvastatin/valsartan (Primary)
- Indications Dyslipidaemias; Hypertension
- Focus Therapeutic Use
- Sponsors EMS
- 14 Oct 2019 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 24 Jan 2018 New trial record